Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Time (in months) from anatomopathological diagnosis to death | over a period of 5 years (Day 0 = anatomopathological diagnosis) |
| Progression Free survival | Time (in months) from anatomopathological diagnosis to progression of the disease assessed by RECIST criteria | over a period of 5 years (Day 0 = anatomopathological diagnosis) |
| Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma | Distribution in percentage of main oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2), assessed by Sanger sequencing or FISH method in histological samples from metastatic lung adenocarcinomas | At base line (Day 0 = anatomopathological diagnosis) |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution in percentage of metastasis sites according oncogenic drivers | Distribution in percentage of metastatic sites assessed by CT-scan for metastatic lung adenocarcinomas according oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2) | At baseline (Day 0 = anatomopathological diagnosis) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with metastatic lung adenocarcinoma diagnosed between 2012 and 2014 with a medical follow-up entirely done in Nancy Central Hospital
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Angelica Tiotiu | Nancy Central Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Régional Universitaire | Vandœuvre-lès-Nancy | Meurthe Et Moselle | 54000 | France |
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077192 | Adenocarcinoma of Lung |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided